美容护理行业周报：诺和盈亮相进博会，开启国内肥胖症治疗的新格局

Investment Rating - The investment rating for the beauty and personal care industry is "Recommended" [2][4][22]. Core Insights - Novo Nordisk's GLP-1RA weekly formulation, Novoing®, was showcased at the China International Import Expo, marking a new era in obesity treatment in China. This drug, approved in June 2024, can achieve an average weight reduction of 17% (16.8 kg) and offers multiple health benefits beyond weight loss [2][18][20]. - The establishment of the Aesthetic & Care Ingredients Business Unit by Prolo Pharma indicates a strategic move into the medical beauty and cosmetic raw materials sector, leveraging its strengths in technological innovation and quality control [3][14]. - The medical beauty sector is characterized by strong market vitality and innovation, with significant consumer potential, prompting recommendations to focus on key companies such as Giant Bio, Haohai Biological, Huaxi Biological, East China Pharmaceutical, and Runben Co., Ltd. [4][22]. Summary by Sections 1. Recent Market Performance - From November 4 to November 8, 2024, the Shenwan Beauty and Personal Care Index rose by 6.46%, with top-performing stocks including Babi Co., Water Sheep Co., and Aimeirong [9]. 2. Industry News - A national emergency drill for medical device safety was successfully conducted, emphasizing the importance of regulatory oversight in the pharmaceutical sector [11]. - Marubi Co. signed a project in the Hengqin Guangdong-Macao Deep Cooperation Zone, focusing on multiple industries including biomedicine and e-commerce [11][12]. 3. Key Company Announcements - Betaini announced a significant share reduction by a major shareholder, while Fulejia adjusted its fundraising project investments to enhance brand marketing [15][16]. - East China Pharmaceutical received a drug registration certificate for a new treatment for moderate to severe plaque psoriasis [16]. 4. Weekly Insights - Novoing®'s introduction at the Import Expo is expected to revolutionize obesity treatment in China, addressing a significant gap in effective clinical options for overweight and obese patients [18][20]. 5. Investment Recommendations - The report suggests focusing on companies with strong growth potential in the medical beauty sector, maintaining a "Recommended" rating for the beauty and personal care industry [4][22].